Literature DB >> 15452286

Motor signs during the course of Alzheimer disease.

N Scarmeas1, G M Hadjigeorgiou, A Papadimitriou, B Dubois, M Sarazin, J Brandt, M Albert, K Marder, K Bell, L S Honig, D Wegesin, Y Stern.   

Abstract

BACKGROUND: Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care.
OBJECTIVE: To describe the progression and identify predictors of individual MOSIs in AD.
METHODS: A cohort of 474 patients with AD at early stages was followed semiannually for up to 13.1 years (mean 3.6 years) in five centers in Europe and the United States. MOSIs were rated using a standardized portion of the Unified Parkinson's Disease Rating Scale. Overall, 3,030 visits/assessments of MOSIs (average 6.4/patient) were performed. Prevalence and incidence rates were calculated, and cumulative risk graphs were plotted for individual non-drug-induced MOSI domains. Rates of change over time taking into account potential covariates were also estimated. With use of each MOSI domain as outcome in Cox models, predictors of MOSI incidence were identified.
RESULTS: At least one MOSI was detected in 13% of patients at first examination and in 36% for the last evaluation. Total MOSI score increased at an annual rate of 3% of total possible score. Rates of annual change for speech/facial expression (4%), rigidity (2.45%), posture/gait (3.9%), and bradykinesia (3.75%) were of similar magnitude, and their occurrence increased from first (3 to 6%) to last (22 to 29%) evaluation. Tremor was less frequent throughout the course of the disease (4% at first and 7% at last evaluation) and worsened less (0.75% increase/year).
CONCLUSIONS: Most motor signs occur frequently and progress rapidly in Alzheimer disease. Tremor is an exception in that it occurs less frequently and advances at slower rates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452286      PMCID: PMC3028531          DOI: 10.1212/01.wnl.0000138440.39918.0c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Progression of parkinsonian signs in Alzheimer's disease.

Authors:  R S Wilson; D A Bennett; D W Gilley; L A Beckett; J A Schneider; D A Evans
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

3.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

4.  An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease.

Authors:  Y Stern; D Jacobs; J Goldman; E Gomez-Tortosa; B T Hyman; Y Liu; J Troncoso; K Marder; M X Tang; J Brandt; M Albert
Journal:  Arch Neurol       Date:  2001-03

5.  Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.

Authors:  A Heyman; G G Fillenbaum; M Gearing; S S Mirra; K A Welsh-Bohmer; B Peterson; C Pieper
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

6.  Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease.

Authors:  Mary N Haan; William J Jagust; Douglas Galasko; Jeffrey Kaye
Journal:  Arch Neurol       Date:  2002-04

7.  Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders.

Authors:  Annette Skraep Nielsen; Rivka Ravid; Wouter Kamphorst; Ole Steen Jørgensen
Journal:  J Alzheimers Dis       Date:  2003-04       Impact factor: 4.472

8.  Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease.

Authors:  N Scarmeas; J Brandt; M Albert; D P Devanand; K Marder; K Bell; A Ciappa; B Tycko; Y Stern
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

9.  The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies.

Authors:  Daniel L Murman; Sherry B Kuo; Michelle C Powell; Christopher C Colenda
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

10.  Depression, intellectual impairment, and Parkinson disease.

Authors:  R Mayeux; Y Stern; J Rosen; J Leventhal
Journal:  Neurology       Date:  1981-06       Impact factor: 9.910

View more
  64 in total

Review 1.  Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer's Disease: an Emerging Issue in Geriatric NeuroHIV.

Authors:  Benedetta Milanini; Victor Valcour
Journal:  Curr HIV/AIDS Rep       Date:  2017-08       Impact factor: 5.071

2.  An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.

Authors:  Christian Wider; Owen A Ross; Kenya Nishioka; Michael G Heckman; Carles Vilariño-Güell; Barbara Jasinska-Myga; Nilufer Erketin-Taner; Rosa Rademakers; Neill R Graff-Radford; Deborah C Mash; Spiridon Papapetropoulos; Ranjan Duara; Hirotake Uchikado; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-01-30       Impact factor: 10.154

3.  Total daily activity measured with actigraphy and motor function in community-dwelling older persons with and without dementia.

Authors:  Bryan D James; Patricia A Boyle; David A Bennett; Aron S Buchman
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Jul-Sep       Impact factor: 2.703

Review 4.  Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence?

Authors:  Hiral LaRoia; Elan D Louis
Journal:  Neuroepidemiology       Date:  2011-07-13       Impact factor: 3.282

5.  Rapid cognitive decline in Alzheimer's disease. Consensus paper.

Authors:  M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

6.  Seizures in Alzheimer disease: who, when, and how common?

Authors:  Nikolaos Scarmeas; Lawrence S Honig; Hyunmi Choi; Julio Cantero; Jason Brandt; Deborah Blacker; Marilyn Albert; Joan C Amatniek; Karen Marder; Karen Bell; W Allen Hauser; Yaakov Stern
Journal:  Arch Neurol       Date:  2009-08

7.  Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study.

Authors:  Florence Portet; Nikolaos Scarmeas; Stephanie Cosentino; Elisabeth P Helzner; Yaakov Stern
Journal:  Arch Neurol       Date:  2009-09

8.  Progressive apraxic agraphia with micrographia presenting as corticobasal syndrome showing extensive Pittsburgh compound B uptake.

Authors:  Yasuhisa Sakurai; Kenji Ishii; Masahiro Sonoo; Yuko Saito; Shigeo Murayama; Atsushi Iwata; Kensuke Hamada; Izumi Sugimoto; Shoji Tsuji; Toru Mannen
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

Review 9.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

10.  The Association Between Alcohol Use and the Progression of Alzheimer's Disease.

Authors:  Devorah Heymann; Yaakov Stern; Stephanie Cosentino; Oksana Tatarina-Nulman; Jhedy N Dorrejo; Yian Gu
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.